tamsulosin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensive substances, prazosin derivatives 2562 106133-20-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tamsulosin
  • tamsulosin hydrochloride
  • tamsulosin HCl
  • LY-253352
A sulfonamide derivative and adrenergic alpha-1 receptor antagonist that is used to relieve symptoms of urinary obstruction caused by BENIGN PROSTATIC HYPERPLASIA.
  • Molecular weight: 408.51
  • Formula: C20H28N2O5S
  • CLOGP: 2.17
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 99.88
  • ALOGS: -4.79
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8.70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.03 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.21 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.62 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 15, 1997 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrolithiasis 149.37 15.47 80 6783 32971 46646228
Urinary tract infection 78.23 15.47 126 6737 220140 46459059
Multiple sclerosis relapse 71.49 15.47 55 6808 42070 46637129
Urinary retention 55.42 15.47 39 6824 26022 46653177
Residual urine volume increased 45.87 15.47 7 6856 18 46679181
Ligament pain 32.15 15.47 7 6856 171 46679028
Respiratory tract inflammation 30.35 15.47 8 6855 447 46678752
Renal colic 30.03 15.47 10 6853 1256 46677943
Rheumatoid arthritis 24.99 15.47 3 6860 240212 46438987
Progressive multifocal leukoencephalopathy 24.15 15.47 17 6846 11329 46667870
Pertussis 23.73 15.47 7 6856 591 46678608
Multiple sclerosis 23.05 15.47 23 6840 24768 46654431
Chorioretinitis 22.94 15.47 6 6857 325 46678874
Sinus pain 22.49 15.47 9 6854 1901 46677298
Disorganised speech 21.14 15.47 7 6856 864 46678335
Drug ineffective 20.74 15.47 43 6820 677795 46001404
Iris disorder 19.70 15.47 4 6859 69 46679130
Immune reconstitution inflammatory syndrome 18.12 15.47 11 6852 5714 46673485
Renal stone removal 17.85 15.47 4 6859 112 46679087
Hypertensive nephropathy 17.29 15.47 5 6858 394 46678805
Urinary tract obstruction 16.43 15.47 7 6856 1731 46677468
Product use issue 16.21 15.47 40 6823 94604 46584595
Central nervous system stimulation 16.11 15.47 3 6860 32 46679167
Erythropenia 15.70 15.47 4 6859 195 46679004

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Iris disorder 745.02 10.46 201 150714 163 29801400
Urinary retention 380.06 10.46 632 150283 32285 29769278
Dizziness 322.32 10.46 1875 149040 193034 29608529
Fall 308.08 10.46 1761 149154 180111 29621452
Cataract operation complication 257.21 10.46 73 150842 86 29801477
Syncope 243.90 10.46 959 149956 83944 29717619
Orthostatic hypotension 240.85 10.46 433 150482 23546 29778017
Drug abuse 223.16 10.46 68 150847 82004 29719559
Iridocele 220.91 10.46 57 150858 30 29801533
Urinary tract infection 194.75 10.46 811 150104 72848 29728715
Toxicity to various agents 189.04 10.46 380 150535 176803 29624760
Floppy iris syndrome 169.36 10.46 63 150852 258 29801305
Procedural complication 165.77 10.46 155 150760 4342 29797221
Completed suicide 133.21 10.46 184 150731 99308 29702255
Dysuria 132.53 10.46 327 150588 22214 29779349
Idiopathic pulmonary fibrosis 125.15 10.46 127 150788 3942 29797621
Benign prostatic hyperplasia 118.36 10.46 199 150716 10248 29791315
Pollakiuria 108.79 10.46 254 150661 16652 29784911
Product prescribing error 93.38 10.46 238 150677 16495 29785068
Prostatomegaly 90.10 10.46 114 150801 4522 29797041
Retrograde ejaculation 83.81 10.46 38 150877 281 29801282
Haematuria 82.77 10.46 445 150470 44389 29757174
Asthenia 81.62 10.46 1566 149349 219724 29581839
Off label use 76.66 10.46 845 150070 248445 29553118
Multiple organ dysfunction syndrome 76.61 10.46 126 150789 63361 29738202
Urinary incontinence 74.67 10.46 221 150694 16719 29784844
Nocturia 74.52 10.46 143 150772 8169 29793394
Pupillary disorder 73.78 10.46 32 150883 210 29801353
Fatigue 70.26 10.46 2112 148803 318561 29483002
Urine flow decreased 69.22 10.46 53 150862 1119 29800444
Atrial fibrillation 67.51 10.46 837 150078 107287 29694276
Drug resistance 66.03 10.46 11 150904 20122 29781441
Intentional overdose 65.85 10.46 67 150848 41414 29760149
Micturition urgency 63.86 10.46 94 150821 4313 29797250
Prostate cancer 63.38 10.46 264 150651 23693 29777870
Presyncope 62.88 10.46 201 150714 15855 29785708
Drug ineffective 62.36 10.46 1276 149639 339111 29462452
Prostatic disorder 61.58 10.46 73 150842 2705 29798858
Miosis 61.56 10.46 127 150788 7649 29793914
Febrile neutropenia 61.04 10.46 303 150612 106390 29695173
Hallucination 57.04 10.46 433 150482 48626 29752937
Hypotension 56.98 10.46 1367 149548 199198 29602365
Prostatic specific antigen increased 56.17 10.46 160 150755 11844 29789719
Cytomegalovirus infection 55.25 10.46 25 150890 23649 29777914
Product monitoring error 54.75 10.46 55 150860 1686 29799877
Drug dependence 53.72 10.46 20 150895 21275 29780288
Cardio-respiratory arrest 51.18 10.46 135 150780 57171 29744392
Confusional state 50.19 10.46 956 149959 133878 29667685
Suicide attempt 49.93 10.46 67 150848 36630 29764933
Abdominal pain lower 46.88 10.46 123 150792 8675 29792888
Respiratory arrest 46.72 10.46 47 150868 29211 29772352
Pyrexia 46.41 10.46 1130 149785 293359 29508204
Overdose 45.68 10.46 244 150671 84093 29717470
Treatment failure 45.49 10.46 65 150850 34614 29766949
Balance disorder 45.20 10.46 327 150588 36166 29765397
Drug reaction with eosinophilia and systemic symptoms 44.09 10.46 47 150868 28441 29773122
Product substitution issue 43.35 10.46 130 150785 9905 29791658
Lower urinary tract symptoms 42.54 10.46 19 150896 135 29801428
Ocular procedural complication 41.82 10.46 15 150900 54 29801509
Ejaculation failure 40.49 10.46 33 150882 765 29800798
Labelled drug-drug interaction medication error 40.42 10.46 131 150784 10407 29791156
Bladder cancer 40.35 10.46 119 150796 8983 29792580
Alanine aminotransferase increased 40.16 10.46 215 150700 74061 29727502
Cystitis 38.58 10.46 111 150804 8263 29793300
Loss of consciousness 38.30 10.46 587 150328 78788 29722775
Bladder disorder 37.14 10.46 58 150857 2805 29798758
Rheumatoid arthritis 36.06 10.46 98 150817 41099 29760464
Cardiac arrest 35.98 10.46 297 150618 92553 29709010
Nephrolithiasis 35.89 10.46 231 150684 24579 29776984
Leukopenia 35.33 10.46 154 150761 56005 29745558
Bradycardia 35.32 10.46 494 150421 65032 29736531
Muscular weakness 35.19 10.46 482 150433 63163 29738400
Cataract operation 35.11 10.46 36 150879 1131 29800432
Cataract 34.53 10.46 208 150707 21627 29779936
Dacryocystitis 34.37 10.46 8 150907 0 29801563
Dyspnoea 34.34 10.46 2028 148887 331267 29470296
Bone marrow failure 34.18 10.46 61 150854 29724 29771839
Memory impairment 34.05 10.46 311 150604 36863 29764700
Gait disturbance 33.80 10.46 547 150368 74230 29727333
Bladder spasm 33.78 10.46 31 150884 847 29800716
Peritonitis 33.38 10.46 35 150880 21340 29780223
Prostatitis 32.96 10.46 75 150840 4832 29796731
Disseminated intravascular coagulation 32.75 10.46 38 150877 22133 29779430
Full blood count decreased 32.45 10.46 161 150754 15556 29786007
Nipple pain 32.15 10.46 26 150889 596 29800967
Constipation 32.11 10.46 770 150145 112136 29689427
Hormone receptor positive breast cancer 31.75 10.46 10 150905 21 29801542
Neutropenia 31.43 10.46 457 150458 128083 29673480
Peripheral swelling 31.14 10.46 456 150459 60618 29740945
Vitreous loss 30.51 10.46 8 150907 5 29801558
Plasmapheresis 30.23 10.46 20 150895 332 29801231
Testicular swelling 30.19 10.46 36 150879 1342 29800221
Hepatic failure 29.78 10.46 81 150834 33962 29767601
Haemophagocytic lymphohistiocytosis 28.67 10.46 7 150908 9784 29791779
Aspergillus infection 28.58 10.46 8 150907 10206 29791357
Graft versus host disease 28.31 10.46 8 150907 10142 29791421
Head injury 28.11 10.46 164 150751 16856 29784707
Product use in unapproved indication 27.51 10.46 238 150677 73455 29728108
Thrombocytopenia 27.00 10.46 507 150408 136537 29665026
Urinary tract obstruction 26.28 10.46 55 150860 3346 29798217
Myocardial infarction 26.24 10.46 460 150455 125165 29676398
Urosepsis 25.86 10.46 115 150800 10617 29790946
Septic shock 25.76 10.46 201 150714 63406 29738157
Wound 25.57 10.46 127 150788 12275 29789288
Blood urine present 25.32 10.46 108 150807 9792 29791771
Dementia 25.27 10.46 127 150788 12334 29789229
Hot flush 25.25 10.46 143 150772 14537 29787026
Bladder catheterisation 25.20 10.46 22 150893 562 29801001
Dizziness postural 25.18 10.46 73 150842 5457 29796106
Poisoning 25.06 10.46 13 150902 11369 29790194
Priapism 24.95 10.46 66 150849 4677 29796886
Intentional self-injury 24.91 10.46 19 150896 13513 29788050
General physical health deterioration 24.13 10.46 667 150248 99277 29702286
Incontinence 23.96 10.46 70 150845 5256 29796307
Immune reconstitution inflammatory syndrome 23.89 10.46 8 150907 9093 29792470
Atrial septal defect 23.50 10.46 3 150912 6698 29794865
Synovitis 23.35 10.46 10 150905 9773 29791790
Faeces discoloured 22.78 10.46 134 150781 13812 29787751
Vomiting 22.64 10.46 892 150023 218926 29582637
Factitious disorder 22.29 10.46 9 150906 48 29801515
Contusion 22.06 10.46 248 150667 31032 29770531
Coma 21.90 10.46 117 150798 40332 29761231
Thrombotic microangiopathy 21.86 10.46 8 150907 8602 29792961
Dry mouth 21.86 10.46 193 150722 22657 29778906
Bladder outlet obstruction 21.79 10.46 12 150903 140 29801423
Haematoma 21.73 10.46 200 150715 23753 29777810
Seizure 21.72 10.46 357 150558 98118 29703445
Platypnoea 21.65 10.46 8 150907 32 29801531
Mucosal inflammation 21.45 10.46 80 150835 30414 29771149
Pallor 21.29 10.46 180 150735 20869 29780694
Toxic epidermal necrolysis 21.26 10.46 36 150879 17904 29783659
Cornea verticillata 21.09 10.46 8 150907 35 29801528
Idiopathic interstitial pneumonia 20.93 10.46 11 150904 116 29801447
Oedema peripheral 20.89 10.46 689 150226 105143 29696420
Drug intolerance 20.82 10.46 138 150777 45153 29756410
Milk-alkali syndrome 20.68 10.46 19 150896 520 29801043
Perineal pain 20.67 10.46 20 150895 585 29800978
Micturition disorder 20.64 10.46 35 150880 1814 29799749
Pneumocystis jirovecii pneumonia 20.61 10.46 34 150881 17086 29784477
Vertigo 20.54 10.46 189 150726 22446 29779117
Hospice care 20.49 10.46 59 150856 4393 29797170
Bladder neck obstruction 20.30 10.46 11 150904 124 29801439
Pancreatitis 20.06 10.46 105 150810 36385 29765178
Prostatic mass 20.00 10.46 7 150908 23 29801540
Aortic stenosis 19.96 10.46 55 150860 3993 29797570
Peritonitis bacterial 19.67 10.46 17 150898 11361 29790202
Intentional product misuse 19.48 10.46 99 150816 34568 29766995
Infusion related reaction 19.46 10.46 122 150793 40442 29761121
Pathogen resistance 19.43 10.46 9 150906 8401 29793162
Agranulocytosis 19.34 10.46 52 150863 21890 29779673
Guillain-Barre syndrome 19.32 10.46 63 150852 5020 29796543
Haematochezia 19.24 10.46 260 150655 33962 29767601
Hepatotoxicity 19.21 10.46 39 150876 18106 29783457
Cytomegalovirus viraemia 19.08 10.46 3 150912 5726 29795837
Dysgeusia 19.04 10.46 200 150715 24601 29776962
Iris atrophy 19.04 10.46 9 150906 74 29801489
Stomal hernia 18.98 10.46 10 150905 106 29801457
Erectile dysfunction 18.95 10.46 156 150759 17946 29783617
Therapeutic product effect incomplete 18.80 10.46 97 150818 33737 29767826
Hepatomegaly 18.63 10.46 14 150901 10033 29791530
Brain oedema 18.58 10.46 21 150894 12377 29789186
Adverse drug reaction 18.41 10.46 188 150727 22957 29778606
Prostatic operation 18.27 10.46 14 150901 296 29801267
Acute respiratory distress syndrome 18.25 10.46 59 150856 23413 29778150
C-reactive protein increased 18.25 10.46 136 150779 43337 29758226
Transaminases increased 18.21 10.46 59 150856 23398 29778165
Periorbital haematoma 18.07 10.46 15 150900 357 29801206
Hydronephrosis 17.82 10.46 91 150824 8892 29792671
Intentional product use issue 17.79 10.46 109 150806 36331 29765232
Urinary hesitation 17.72 10.46 37 150878 2247 29799316
Palpitations 17.63 10.46 252 150663 33321 29768242
Resting tremor 17.60 10.46 18 150897 564 29800999
Iris haemorrhage 17.57 10.46 5 150910 6 29801557
Drug hypersensitivity 17.29 10.46 242 150673 68277 29733286
Ageusia 17.28 10.46 90 150825 8863 29792700
Candida infection 17.14 10.46 32 150883 15330 29786233
Aspartate aminotransferase increased 17.09 10.46 221 150694 63201 29738362
Hepatitis C 17.07 10.46 25 150890 13180 29788383
Diabetic neuropathy 16.83 10.46 51 150864 3908 29797655
Myelosuppression 16.67 10.46 8 150907 7314 29794249
Transurethral prostatectomy 16.56 10.46 14 150901 342 29801221
Hypoacusis 16.53 10.46 125 150790 14014 29787549
Stress 16.34 10.46 50 150865 20185 29781378
Metabolic acidosis 16.29 10.46 116 150799 37345 29764218
Bladder discomfort 16.19 10.46 9 150906 107 29801456
Back pain 16.11 10.46 651 150264 101945 29699618
Urinary tract disorder 16.10 10.46 33 150882 1978 29799585
Post micturition dribble 16.04 10.46 5 150910 10 29801553
Osteonecrosis 15.98 10.46 36 150879 16099 29785464
Prostate cancer metastatic 15.96 10.46 59 150856 5008 29796555
Dacryostenosis acquired 15.93 10.46 10 150905 151 29801412
Hepatocellular injury 15.92 10.46 70 150845 25401 29776162
Taste disorder 15.88 10.46 46 150869 3437 29798126
Angle closure glaucoma 15.79 10.46 19 150896 715 29800848
Blood bilirubin increased 15.67 10.46 114 150801 36522 29765041
Megakaryocytes increased 15.64 10.46 7 150908 50 29801513
Dysphagia 15.59 10.46 385 150530 56313 29745250
Urinary bladder haemorrhage 15.54 10.46 29 150886 1622 29799941
Subdural haematoma 15.52 10.46 155 150760 18817 29782746
Hepatitis 15.50 10.46 59 150856 22297 29779266
Hypertriglyceridaemia 15.39 10.46 11 150904 8087 29793476
Puncture site haematoma 15.27 10.46 10 150905 163 29801400
Tendon pain 15.21 10.46 37 150878 2490 29799073
Bronchopulmonary aspergillosis 15.16 10.46 24 150891 12260 29789303
Prostatism 15.14 10.46 12 150903 267 29801296
Post transplant lymphoproliferative disorder 15.14 10.46 4 150911 5302 29796261
Hip fracture 15.13 10.46 102 150813 11022 29790541
Pancytopenia 15.12 10.46 320 150595 84732 29716831
Burning feet syndrome 15.01 10.46 8 150907 87 29801476
Sperm concentration zero 14.96 10.46 4 150911 3 29801560
Bovine tuberculosis 14.92 10.46 9 150906 126 29801437
Executive dysfunction 14.92 10.46 9 150906 126 29801437
Breast disorder male 14.87 10.46 5 150910 14 29801549
Cystitis haemorrhagic 14.87 10.46 3 150912 4784 29796779
Macular degeneration 14.75 10.46 32 150883 1996 29799567
Acute hepatic failure 14.70 10.46 23 150892 11804 29789759
Arteriovenous fistula 14.68 10.46 17 150898 614 29800949
Gallbladder hypofunction 14.62 10.46 5 150910 15 29801548
Prostatic obstruction 14.62 10.46 9 150906 131 29801432
Gait inability 14.49 10.46 152 150763 18689 29782874
Stevens-Johnson syndrome 14.45 10.46 43 150872 17513 29784050
Myxoedema coma 14.44 10.46 12 150903 286 29801277
Hepatic enzyme increased 14.43 10.46 104 150811 33390 29768173
Diabetes mellitus 14.40 10.46 138 150777 41727 29759836
Benign gastrointestinal neoplasm 14.39 10.46 9 150906 135 29801428
Transient ischaemic attack 14.39 10.46 192 150723 25008 29776555
Suprapubic pain 14.33 10.46 13 150902 350 29801213
Hyponatraemic syndrome 14.30 10.46 11 150904 234 29801329
Psoriasis 14.25 10.46 141 150774 42365 29759198
Breast tenderness 14.22 10.46 18 150897 714 29800849
Muscle spasms 14.06 10.46 427 150488 64411 29737152
Tuberculosis 14.04 10.46 12 150903 8065 29793498
Paraplegia 13.97 10.46 37 150878 2624 29798939
Loss of bladder sensation 13.90 10.46 7 150908 67 29801496
Product prescribing issue 13.89 10.46 19 150896 814 29800749
Renal tubular disorder 13.86 10.46 4 150911 5002 29796561
Urogenital disorder 13.75 10.46 6 150909 40 29801523
Haematotoxicity 13.65 10.46 7 150908 6163 29795400
Mydriasis 13.55 10.46 7 150908 6136 29795427
Blood pressure systolic 13.55 10.46 4 150911 6 29801557
Metastases to neck 13.55 10.46 4 150911 6 29801557
Dysstasia 13.50 10.46 95 150820 10410 29791153
Arteriosclerotic gangrene 13.47 10.46 7 150908 72 29801491
Herpes simplex 13.45 10.46 3 150912 4461 29797102
Intestinal haemorrhage 13.38 10.46 41 150874 3160 29798403
Status epilepticus 13.32 10.46 22 150893 11050 29790513
Daydreaming 13.25 10.46 14 150901 456 29801107
Wrong schedule 13.20 10.46 8 150907 113 29801450
Calculus bladder 13.12 10.46 19 150896 859 29800704
Hepatic steatosis 13.08 10.46 35 150880 14758 29786805
Serum ferritin abnormal 13.06 10.46 10 150905 211 29801352
Testicular pain 13.02 10.46 37 150878 2735 29798828
Ascites 12.96 10.46 117 150798 35804 29765759
Psychotic disorder 12.92 10.46 60 150855 21455 29780108
Lymphadenopathy 12.92 10.46 71 150844 24305 29777258
Prostatic acid phosphatase increased 12.89 10.46 3 150912 0 29801563
Pupillary block 12.89 10.46 3 150912 0 29801563
Iris injury 12.89 10.46 3 150912 0 29801563
Hyponatraemia 12.86 10.46 436 150479 66766 29734797
Acidosis 12.83 10.46 20 150895 10281 29791282
Respiratory depression 12.80 10.46 24 150891 11479 29790084
Breast enlargement 12.74 10.46 13 150902 406 29801157
Tubulointerstitial nephritis 12.54 10.46 47 150868 17844 29783719
Oesophageal rupture 12.54 10.46 13 150902 414 29801149
Lymphopenia 12.53 10.46 30 150885 13133 29788430
Pain in extremity 12.50 10.46 677 150238 109544 29692019
Flatulence 12.45 10.46 143 150772 17986 29783577
Frostbite 12.42 10.46 6 150909 52 29801511
Femoral artery aneurysm 12.34 10.46 9 150906 176 29801387
Dental restoration failure 12.33 10.46 5 150910 27 29801536
Choroidal detachment 12.26 10.46 12 150903 356 29801207
Phaeochromocytoma malignant 12.23 10.46 6 150909 54 29801509
Invasive ductal breast carcinoma 12.22 10.46 4 150911 10 29801553
Lichen sclerosus 12.22 10.46 4 150911 10 29801553
Pharyngeal cancer 12.18 10.46 5 150910 28 29801535
Product use issue 12.15 10.46 161 150754 45855 29755708
Food aversion 12.13 10.46 11 150904 296 29801267
Hepatic function abnormal 12.11 10.46 144 150771 41801 29759762
Neurogenic bladder 12.08 10.46 26 150889 1613 29799950
Psoriatic arthropathy 11.99 10.46 40 150875 15721 29785842
Lip swelling 11.86 10.46 107 150808 12637 29788926
Haematospermia 11.81 10.46 12 150903 373 29801190
Urethral pain 11.76 10.46 5 150910 31 29801532
Haemorrhage urinary tract 11.76 10.46 26 150889 1643 29799920
Posterior reversible encephalopathy syndrome 11.73 10.46 16 150899 8691 29792872
Chronic obstructive pulmonary disease 11.73 10.46 310 150605 45816 29755747
Blood creatine phosphokinase increased 11.73 10.46 153 150762 43695 29757868
Rectal haemorrhage 11.71 10.46 244 150671 34695 29766868
Cytokine release syndrome 11.71 10.46 20 150895 9913 29791650
Bedridden 11.70 10.46 43 150872 3639 29797924
Hypertonic bladder 11.67 10.46 18 150897 861 29800702
Hepatocellular carcinoma 11.65 10.46 19 150896 9591 29791972
Pulmonary tuberculosis 11.53 10.46 5 150910 4852 29796711
Drug withdrawal syndrome 11.45 10.46 56 150859 19753 29781810
Iris adhesions 11.44 10.46 9 150906 198 29801365
Colitis ulcerative 11.42 10.46 36 150879 14398 29787165
Multiple system atrophy 11.40 10.46 9 150906 199 29801364
Cerebral haematoma 11.36 10.46 49 150866 4465 29797098
Subdural hygroma 11.34 10.46 11 150904 323 29801240
Extrapyramidal disorder 11.30 10.46 23 150892 10670 29790893
Drug dispensed to wrong patient 11.30 10.46 8 150907 149 29801414
Akathisia 11.24 10.46 8 150907 5896 29795667
Bladder pain 11.23 10.46 12 150903 396 29801167
Faecaloma 11.22 10.46 48 150867 4357 29797206
Nephropathy toxic 11.15 10.46 23 150892 10616 29790947
Therapy non-responder 11.04 10.46 95 150820 29358 29772205
Hypoxia 11.03 10.46 172 150743 47682 29753881
Blood loss anaemia 11.02 10.46 71 150844 7556 29794007
Gynaecomastia 11.02 10.46 76 150839 8275 29793288
Visual impairment 11.01 10.46 215 150700 30223 29771340
Blood glucose fluctuation 11.01 10.46 42 150873 3619 29797944
Wound haematoma 10.97 10.46 6 150909 69 29801494
Bulbar palsy 10.92 10.46 9 150906 212 29801351
Bladder obstruction 10.91 10.46 14 150901 563 29801000
Urinary retention postoperative 10.89 10.46 6 150909 70 29801493
Hepatic necrosis 10.86 10.46 3 150912 3860 29797703
Atrioventricular block first degree 10.85 10.46 57 150858 5631 29795932
Inadequate osteointegration 10.83 10.46 4 150911 16 29801547
Electrocardiogram RR interval prolonged 10.82 10.46 3 150912 3 29801560
Anorectal operation 10.82 10.46 3 150912 3 29801560
Respiratory distress 10.79 10.46 110 150805 32862 29768701
Radiation inflammation 10.75 10.46 7 150908 113 29801450
Skin laceration 10.74 10.46 95 150820 11156 29790407
Electrocardiogram QT prolonged 10.74 10.46 122 150793 35713 29765850
Sinus tachycardia 10.69 10.46 41 150874 15463 29786100
Renal haematoma 10.63 10.46 13 150902 498 29801065
Palatal oedema 10.55 10.46 16 150899 754 29800809
Halo vision 10.52 10.46 8 150907 167 29801396
International normalised ratio increased 10.51 10.46 315 150600 47424 29754139
Spinal fracture 10.49 10.46 64 150851 6684 29794879
Blood pressure decreased 10.47 10.46 311 150604 46764 29754799
Substance abuse 10.47 10.46 12 150903 7028 29794535

Pharmacologic Action:

SourceCodeDescription
ATC G04CA02 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
ATC G04CA52 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
ATC G04CA53 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
ATC G04CA54 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
FDA MoA N0000000099 Adrenergic alpha-Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:37890 alpha-adrenoceptor antagonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Benign prostatic hyperplasia indication 266569009
Priapism contraindication 6273006 DOID:9286
Orthostatic hypotension contraindication 28651003
Oligozoospermia contraindication 88311004
Cataract surgery contraindication 110473004
Disease of liver contraindication 235856003 DOID:409
Syncope contraindication 271594007
Pregnancy, function contraindication 289908002
Dizziness contraindication 404640003
Breastfeeding (mother) contraindication 413712001
Intraoperative floppy iris syndrome contraindication 418801006
High-Grade Prostate Cancer contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.71 acidic
pKa2 8.16 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1A GPCR Ki 9.10 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 7.87 CHEMBL
D(2) dopamine receptor GPCR Ki 7.89 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 10.24 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 10.54 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 9.21 CHEMBL
D(3) dopamine receptor GPCR Ki 9.55 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 8.10 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 7.08 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 9.70 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 8.17 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 10.15 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 10.52 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 6.03 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 9.90 CHEMBL

External reference:

IDSource
4024076 VUID
N0000022081 NUI
D01024 KEGG_DRUG
106463-17-6 SECONDARY_CAS_RN
4021051 VANDF
4024076 VANDF
C0636157 UMLSCUI
CHEBI:9398 CHEBI
CHEMBL836 ChEMBL_ID
CHEMBL1200914 ChEMBL_ID
D000077409 MESH_DESCRIPTOR_UI
6750 INN_ID
DB00706 DRUGBANK_ID
G3P28OML5I UNII
6917671 PUBCHEM_CID
488 IUPHAR_LIGAND_ID
236495 RXNORM
171693 MMSL
20642 MMSL
5541 MMSL
d04121 MMSL
006115 NDDF
006116 NDDF
108559004 SNOMEDCT_US
108560009 SNOMEDCT_US
372509005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
FLOMAX HUMAN PRESCRIPTION DRUG LABEL 1 0024-5837 CAPSULE 0.40 mg ORAL NDA 30 sections
JALYN HUMAN PRESCRIPTION DRUG LABEL 2 0173-0809 CAPSULE 0.40 mg ORAL NDA 29 sections
Tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2996 CAPSULE 0.40 mg ORAL ANDA 19 sections
Flomax HUMAN PRESCRIPTION DRUG LABEL 1 0597-0058 CAPSULE 0.40 mg ORAL NDA 27 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7995 CAPSULE 0.40 mg ORAL ANDA 26 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8055 CAPSULE 0.40 mg ORAL ANDA 27 sections
tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2076 CAPSULE 0.40 mg ORAL ANDA 27 sections
tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6401 CAPSULE 0.40 mg ORAL ANDA 27 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10370-169 CAPSULE 0.40 mg ORAL ANDA 26 sections
Dutasteride and Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 10370-280 CAPSULE 0.40 mg ORAL ANDA 26 sections
Tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-280 CAPSULE 0.40 mg ORAL ANDA 18 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10544-550 CAPSULE 0.40 mg ORAL ANDA 17 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-298 CAPSULE 0.40 mg ORAL ANDA 17 sections
FLOMAX HUMAN PRESCRIPTION DRUG LABEL 1 16590-489 CAPSULE 0.40 mg ORAL NDA 28 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 16714-713 CAPSULE 0.40 mg ORAL ANDA 26 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 33261-839 CAPSULE 0.40 mg ORAL ANDA 17 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 33342-159 CAPSULE 0.40 mg ORAL ANDA 27 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42254-012 CAPSULE 0.40 mg ORAL ANDA 17 sections
Tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-264 CAPSULE 0.40 mg ORAL ANDA 19 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-725 CAPSULE 0.40 mg ORAL ANDA 27 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-947 CAPSULE 0.40 mg ORAL ANDA 27 sections
tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43353-013 CAPSULE 0.40 mg ORAL ANDA 27 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 43353-019 CAPSULE 0.40 mg ORAL ANDA 26 sections
Tamsulosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43353-663 CAPSULE 0.40 mg ORAL ANDA 19 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 50090-1846 CAPSULE 0.40 mg ORAL ANDA 27 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 50090-3646 CAPSULE 0.40 mg ORAL ANDA 29 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 50090-4906 CAPSULE 0.40 mg ORAL ANDA 29 sections
Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-740 CAPSULE 0.40 mg ORAL ANDA 30 sections
Tamsulosin Hydrochloride Human Prescription Drug Label 1 50436-0598 CAPSULE 0.40 mg ORAL ANDA 27 sections
TAMSULOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51655-677 CAPSULE 0.40 mg ORAL ANDA 14 sections